Proteasome-dependent degradation of Chk1 kinase induced by the topoisomerase II inhibitor R16 contributes to its anticancer activity

Cancer Biology and Therapy

Volumn 7, Issue 11, 2008, Pages 1726-1731

  Feng, Jian Ming ^a   Zhu, Hong ^a   Zhang, Xiao Wei ^a   Ding, Jian ^a   Miao, Ze Hong ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Anticancer activity; Chk1; Colon carcinoma; Naphthalimide; Proteasome; R16; Topoisomerase II inhibitor

Indexed keywords

2 (2 DIMETHYLAMINO) 6 THIA 2 AZA BENZO [DEF] CHRYSENE 1,3 DIONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BIPINDOGENIN BETA XYLOSYL BETA ALLOSIDE; CHECKPOINT KINASE 1; GYRASE INHIBITOR; HEAT SHOCK PROTEIN 90; LACTACYSTIN; MESSENGER RNA; NAPHTHALIMIDE DERIVATIVE; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG; 2-(2-DIMETHYLAMINO)-6-THIA-2-AZABENZO(DEF)CHRYSENE-1,3-DIONE; ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; ENZYME INHIBITOR; LEUPEPTIN; PROTEIN KINASE; THIOPHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL KILLING; CELL STRAIN HCT116; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PHOSPHORYLATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; UBIQUITINATION; ANALOGS AND DERIVATIVES; FLOW CYTOMETRY; METABOLISM; PROCEDURES; TIME; TUMOR CELL LINE;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; ENZYME INHIBITORS; FLOW CYTOMETRY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LEUPEPTINS; NAPHTHALIMIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; THIOPHENES; TIME FACTORS; TOPOISOMERASE II INHIBITORS; UBIQUITIN;

EID: 56449089043     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.11.6728     Document Type: Article

References (20)

1. Scheithauer W, Dittrich C, Kornek G, Haider K, Linkesch W, Gisslinger H, Depisch D. Phase II study of amonafide in advanced breast cancer. Breast Cancer Res Treat 1991; 20:63-7.
2. Costanza ME, Berry D, Henderson IC, Ratain MJ, Wu K, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss AP. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer-a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res 1995; 1:699-704.
3. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991; 50:573-9.
4. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 1993; 53:2304-8.
5. 2-M arrest via poisoning topoisomerase II. Molecular cancer therapeutics 2007; 6:484-95.
6. Haruki N, Saito H, Tatematsu Y, Konishi H, Harano T, Masuda A, Osada H, Fujii Y, Takahashi T. Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 2000; 60:4689-92.
7. Zhou J, Schmid T, Frank R, Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. The Journal of biological chemistry 2004; 279:13506-13.
8. Miao ZH, Tong LJ, Zhang JS, Han JX, Ding J. Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line. Int J Cancer 2004; 110:627-32.
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8.
10. Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F, Abraham RT. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Molecular cell 2005; 19:607-18.
11. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NFkappaB1 precursor protein and the activation of NFkappaB. Cell 1994; 78:773-85.
12. Tomoda H, Omura S. Lactacystin, a proteasome inhibitor: discovery and its application in cell biology. Yakugaku Zasshi 2000; 120:935-49.
13. Schwartz AL, Ciechanover A. Ubiquitin-mediated protein modification and degradation. Am J Respir Cell Mol Biol 1992; 7:463-8.
14. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. The Journal of biological chemistry 2003; 278:52572-7.
15. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65:635-92.
16. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58:351-75.
17. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes & development 2001; 15:2177-96.
18. 2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98:523-8.
19. Zachos G, Black EJ, Walker M, Scott MT, Vagnarelli P, Earnshaw WC, Gillespie DA. Chk1 is required for spindle checkpoint function. Developmental cell 2007; 12:247-60.
20. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13:1955-60.